medigraphic.com

2012, Number 2

<< Back Next >>

Enf Infec Microbiol 2012; 32 (2)

Probiotic use in pediatrics

Miranda NMG, Cruz GE

Language: Spanish
References: 38
Page: 74-80
PDF size: 120.12 Kb.


ABSTRACT

Probiotics are preparations or components of microbial viable cells which given in adequate doses have a beneficial effect on the host’s health. They must be of human origin, nonpathogenic, resistant to processing, stable in bile and acid secretions, have the capacity of adherence to the epithelial wall, be able to persist in the gastrointestinal tract and influence in local metabolic activity. The two main bacterial genera that meet these characteristics are the genera Lactobacillus and Bifidobacterium. In this paper we analyze their possible indications and risks.


REFERENCES

  1. Seppo S, Isolauri E. “Intestinal colonization microbiota and probiotics”. J Pediatr 2006; 49:5115-5120.

  2. Backhed F, Ley RE, Sonnenburg JL. “Host bacterial mutualism in the human intestine”. Science 2005;307:1915-20.

  3. Grunulund MM, Aruilummi H. Kero P. “Importance of intestinal colonization in the maturation of humoral immunity in early infancy: a prospective follow-up study of healthy infants aged 0-6 months”. Arch Dis Child 2000; 83:F186-92.

  4. De Morais MB, Abe Jacob MC. “The role of probiotics and prebiotics in pediatric practice”. J Pediatr (Rio J) 2006;82(5 Suppl):S189-97.

  5. Goldin BR, Gorbach SL. “Clinical indications for probiotics: an overview”. Clin Infect Dis 2008 Feb 1;46 Suppl 2:S96-100.

  6. International Human Genome Sequencing Consortium. “Initial sequencing and analysis of human genome”. Nature 2001; 409:860-921.

  7. Hetge DJ. “Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius”. Inmunology 2006:118;205-215.

  8. Que JU, Caset SW, Hetge DJ. “Factors responsible for increased susceptibility of mice to intestinal colonization after treatment with streptomycin”. Infect Immun 1986; 53:116-123.

  9. LeeJ, Ji-Hun M, Shen C. “Toll-like receptor signaling in intestinal epithelial cell contributes to colonic homeostasis”. Gastroenterol 2007; 23:23-31.

  10. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. “Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials”. Lancet Infect Dis 2006;6:374-82.

  11. Szajewska H, Ruszczyn´ Ski H, Radzikowski A. “Probiotics In The Prevention Of Antibiotic-Associated Diarrhea In Children: A Meta-Analysis Of Randomized Controlled Trials”. J Pediatr 2006;149:367-72.

  12. Johnston BC, Supina AL, Ospina M, Vohra S. “Probiotics for the prevention of pediatric antibiotic-associated diarrhea". Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD004827. DOI: 10.1002/14651858. CD004827.pub2.

  13. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. “Probiotics for treating infectious diarrhea”. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD003048. DOI: 10.1002/14651858.CD003048.pub2.

  14. Szajewska H, Skórka A, Dylag M. “Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children”. Aliment Pharmacol Ther. 2007 Feb 1;25(3):257-64.

  15. Salazar-Lindo E, Figueroa-Quintanilla D, Caciano MI, Reto-Valiente V, Chauviere G, Colin P for the Lacteol Study Group. “Effectiveness and Safety of Lactobacillus LB in the Treatment of Mild Acute Diarrhea in Children”. JPGN 2007;44:571–576 .

  16. Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, Vincenzo A, Albano F, Passariello A, De Marco G, Manguso F, Guarino A. “Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations”. BMJ 2007;335;340.

  17. Petschowr BW, Figueroa R, Harris CL. “Effects of feeding an infant formula containing Lactobacillus GG on the colonization of the intestine: a dose response study in healthy infants”. J Clin Gastroenterol 2005; 39:786-790.

  18. Millar M, Wilkes M. “Probiotics for preterm infants?” Arch Dis Child Fetal Neonatal 2003; 88:F354-F358.

  19. Honeycutt TC, El Khashab M, Wardrop RM 3rd, McNeal- Trice K, “Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial”. Pediatr Crit Care Med 2007;8(5):499-501.

  20. Srinivasan R, Meyer R, Padmanabhan R, Britto J. “Clinical safety of Lactobacillus casei shirota as a probiotic in critically ill children”. J Pediatr Gastroenterol Nutr 2006;42(2):171-3

  21. Lin HC, Su BH, Chen AC, Tsung WL, Chang HT, Tsu FY, William O. “Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants”. Pediatrics 2005;115:1-4.

  22. Kitajima H, Sumida Y, Tanaka R, Pinaki P. “Early administration of Bifidobacterium breve to preterm infants; randomized controlled trial”. Arch Dis Child Fetal Neonatal 1997; 70:F101-F107.

  23. Dani C, Bradaroli R, Bertinni G, Martelli E. “Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants”. Biol Neonate 2002;82:103-108.

  24. Manzoni P, Mostert M, Leonessa L, Priolo C, Farina D. “Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a Randomized Study”. Clin Infect Dis 2006;42:1735-1742.

  25. Hammerman C, Kaplan M. “Probiotics and neonatal intestinal infection”. Curr Opin Infect Dis 2006;19:277-282.

  26. Honeycutt TC, El Khashab M, Wardrop RM 3rd, McNeal-Trice K, “Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial”. Pediatr Crit Care Med 2007;8(5):499-501.

  27. Bausserman M, Michail S. “The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial”. J Pediatr 2005;147(2):197–201.

  28. Banaszkiewicz A, Szajewska H. “Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial”. J Pediatr 2005;146(3):364–9.

  29. Savino F, Pelle E, Palumeri E, et al. “Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study”. Pediatrics 2007;119:124–30.

  30. Lee J, Seto D, Bielory L. “Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis”. J Allergy Clin Immunol 2008;121:116-21.

  31. Yoo J, Tcheurekdjian H, Lynch S.V, Cabana M, Boushey HA. “Microbial Manipulation of Immune Function for Asthma Prevention. Inferences from Clinical Trials”. Proc Am Thorac Soc 2007; 4: 277–82.

  32. Land MH, Rouster K, Woods CR, Cannon ML, Cnota J, Shetty AK. “Lactobacillus sepsis associated with probiotic therapy”. Pediatrics 2005; 115:178-181.

  33. De Groote MA, Frank DN, Dowell E, Glode MP, Pace NR. “Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome”. Pediatr Infect Dis J 2005:24(3);278-80.

  34. Ledoux D, Labombardi VJ, Karter D. “Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin’s disease”. Int J STD AIDS. 2006:17(4);280-2.

  35. Sullivan A, Nord CE “Probiotic lactobacilli and bacteraemia in Stockholm”. Scand J Infect Dis 2006;38(5);327-31.

  36. Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, Sarna S, Valtonen V, Järvinen A. “Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland”. Clin Infect Dis 2002 :35(10);1155-60.

  37. Vankerckhoven V, Moreillon P, Piu S, Giddey M, Huys G, Vancanneyt M, Goossens H. “Infectivity of Lactobacillus rhamnosus and Lactobacillus paracasei isolates in a rat model of experimental endocarditis”. J Med Microbiol 2007;56;1017-24.

  38. Snydman DR. “The safety of probiotics”. Clin Infect Dis 2008:1(46) Suppl 2:S104-11.




2020     |     www.medigraphic.com